Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPC | P11150 | 16/20 | 0.56 |
| ▸ | LIPG | Q9Y5X9 | 16/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20972671 | 0.86 | LIPC (0.49) | LIPCLIPGRAB9ANPC1CYP1A2 | |
| SCHEMBL19709504 | 0.85 | LIPG (0.75) | LIPCLIPG | |
| SCHEMBL20972622 | 0.83 | LIPG (0.48) | LIPCLIPG | |
| SCHEMBL19709492 | 0.81 | LIPC (0.42) | LIPCLIPGEGLN1 | |
| SCHEMBL16899384 | 0.79 | LIPG (0.57) | LIPCLIPG | |
| SCHEMBL19709635 | 0.78 | LIPG (0.48) | LIPCLIPG | |
| SCHEMBL16899468 | 0.77 | LIPG (0.56) | LIPCLIPG | |
| SCHEMBL20972736 | 0.75 | LIPC (0.80) | LIPCLIPG | |
| SCHEMBL19709499 | 0.72 | LIPC (0.42) | LIPCLIPGEGLN1 | |
| SCHEMBL20972735 | 0.72 | LIPG (1.00) | LIPCLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597370-B2 | 2-(benzothiazol-2-yl)-2-cyano-acetamide derivatives and their use as endothelial lipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190144403-A1 | 2-(BENZOTHIAZOL-2-YL)-2-CYANO-ACETAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-05-16 | — | — | US | disclosed |
| WO-2017214005-A1 | 2-(BENZOTHIAZOL-2-YL)-2-CYANO-ACETAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144403-A1 | 2-(BENZOTHIAZOL-2-YL)-2-CYANO-ACETAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIAL LIPASE INHIBITORS | LIPG, LPL, CEL | LIPC 7/4885LIPG 1/4885RAB9A 4474/4885 |
| US-10597370-B2 | 2-(benzothiazol-2-yl)-2-cyano-acetamide derivatives and their use as endothelial lipase inhibitors | LIPG, LPL, CEL | LIPC 7/4885LIPG 1/4885RAB9A 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.